Navigating Relapsed/Refractory CLL/SLL Together: Where Disease-, Treatment-, and Patient-Centered Care Unite is organized by Medscape, LLC.
CME / ABIM MOC / CE Released: July 05, 2024
Valid for credit through: July 05, 2025
Description:
The goal of this activity is for learners to be better able to integrate evidence-based and patient-centered strategies for the management of R/R CLL/small lymphocytic lymphoma (SLL) and consider how the treatment algorithm may evolve with novel targeted strategies.
Learning Objectives:
Upon completion of this activity, participants will:
• Analyze the recent clinical trial data on Bruton tyrosine kinase (BTK) inhibitors for the treatment of R/R CLL/SLL
• Recognize the factors that inform treatment decision-making for the individual patient with R/R CLL/SLL
• Create personalized treatment strategies for patients with R/R CLL/SLL
• Apply effective communication strategies to individualize therapies based on patients’ needs and empower shared decision-making
Accreditation Statements
• Developed through a strategic collaboration between Medscape Global Oncology and Lymphoma Coalition.
• In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
For Physicians
• Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
• The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
• College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
• Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
For Nurses
Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.
For Pharmacists
Medscape designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Activity Number: JA0007105-0000-24-236-H01-P).
Copyrights © 2026 eMedEvents Corporation, All Rights Reserved